Alteplase (recombinant tissue plasminogen activator, r‐TPA) as a thrombolytic agent is primarily indicated in patients suffering from acute ST‐segment elevation myocardial infarction (STEMI), acute ischemic stroke, and pulmonary embolism. The gene discussed is PLAT; the disease is pulmonary embolism.